Geneseeq Receives NMPA Approval for PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Gene Fusion Detection Kit has received marketing authorization from China's National Medical Products Administration (NMPA). The assay is approved as a companion diagnostic (CDx) test for Roche's ROZLYTREK ® (entrectinib) This milestone marks China's first next-generation sequencing (NGS)-based pan-solid tumor NGS CDx test, and it is also the first approved assay for detecting NTRK1/2/3 gene fusions. PanTRKare (CNW Group/Geneseeq Technology Inc.) Addressing Unmet Clinical Needs: Shedding Light on Rare Mutations NTRK gene family fusions occur in less than 1% of all solid tumors, but represent one of the most actionable oncogenic alterations across cancer types. Patients harboring these fusions can benefit from TRK inhibitors such as ROZLYTREK ® . PanTRKare™ enables accurate, sensitive detection of NTRK1/2/3 fusions across diverse tumor types, bringing precision medicine to patients who harbor this rare but important type of mutations. Robust Clinical Validation Across 33 Tumor
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche (OTCMKTS:RHHBY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis) [Yahoo! Finance]Yahoo! Finance
- Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
- Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer SymposiumBusiness Wire
- Roche shares hit milestone with 19% November surge on breast cancer and promising MS drug trials [Seeking Alpha]Seeking Alpha